1h Free Analyst Time
The publisher has been monitoring the benign prostatic hyperplasia (BPH) devices market and it is poised to grow by $ 3.34 bn during 2022-2026, accelerating at a CAGR of 5.09% during the forecast period. Our report on the benign prostatic hyperplasia (BPH) devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of BPH coupled with increasing risk factors, emergence of innovative technologies, and rise in demand for laser therapy as an effective alternative to TURP.
The benign prostatic hyperplasia (BPH) devices market analysis includes the therapy segment and geographic landscape.
The publisher's benign prostatic hyperplasia (BPH) devices market is segmented as below:
By Therapy
- TURP
- Laser therapy
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increasing preference of in-office based minimally invasive surgical techniques as one of the prime reasons driving the benign prostatic hyperplasia (BPH) devices market growth during the next few years. Also, growing popularity of robotic-assisted surgery for BPH and key development will lead to sizable demand in the market.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on benign prostatic hyperplasia (BPH) devices market covers the following areas:
- Benign prostatic hyperplasia (BPH) devices market sizing
- Benign prostatic hyperplasia (BPH) devices market forecast
- Benign prostatic hyperplasia (BPH) devices market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading benign prostatic hyperplasia (BPH) devices market vendors that include Astellas Pharma Inc., biolitec AG, Boston Scientific Corp., Butterfly Medical, Coloplast AS, Convergent Laser Technologies, IPG Photonics Corp., KARL STORZ SE and Co. KG, Medeon Biodesign Inc., Medifocus Inc., Olympus Europa SE and Co. KG, OmniGuide Holdings Inc., ProArc Medical, PROCEPT BioRobotics Corp., Richard Wolf GmbH, SRS Medical, Teleflex Inc., Urologix LLC, Vendor Credentialing Service LLC dba symplr, and Zenflow Inc. Also, the benign prostatic hyperplasia (BPH) devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Exhibits:
Executive Summary
The publisher recognizes the following companies as the key players in the global benign prostatic hyperplasia (BPH) devices market: Astellas Pharma Inc., biolitec AG, Boston Scientific Corp., Butterfly Medical, Coloplast AS, Convergent Laser Technologies, IPG Photonics Corp., KARL STORZ SE and Co. KG, Medeon Biodesign Inc., Medifocus Inc., Olympus Europa SE and Co. KG, OmniGuide Holdings Inc., ProArc Medical, PROCEPT BioRobotics Corp., Richard Wolf GmbH, SRS Medical, Teleflex Inc., Urologix LLC, Vendor Credentialing Service LLC dba symplr, and Zenflow Inc.Commenting on the report, an analyst from the publisher said: "The latest trend gaining momentum in the market is increasing preference of in-office based minimally invasive surgical techniques."
According to the report, one of the major drivers for this market is the increasing prevalence of BPH coupled with increasing risk factors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc.
- Biolitec AG
- Boston Scientific Corp.
- Butterfly Medical
- Coloplast As
- Convergent Laser Technologies
- Ipg Photonics Corp.
- Karl Storz Se and Co. Kg
- Medeon Biodesign Inc.
- Medifocus Inc.
- Olympus Europa Se and Co. Kg
- Omniguide Holdings Inc.
- Proarc Medical
- Procept Biorobotics Corp.
- Richard Wolf GmbH
- Srs Medical
- Teleflex Inc.
- Urologix LLC
- Vendor Credentialing Service LLC Dba Symplr
- Zenflow Inc.